3-Methoxymethcathinone

3-Methoxymethcathinone
Clinical data
Other names3-MeOMC; meta-Methoxymethcathinone; m-MeOMC; 3-Methoxy-N-methylcathinone; 3-Methoxy-N-methyl-β-ketoamphetamine; 3-Methoxy-α,N-dimethyl-β-ketophenethylamine
Drug classSerotonin–dopamine releasing agent; Stimulant[1][2]
Identifiers
  • 1-(3-methoxyphenyl)-2-(methylamino)propan-1-one
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC11H15NO2
Molar mass193.246 g·mol−1
3D model (JSmol)
  • CC(C(=O)C1=CC(=CC=C1)OC)NC
  • InChI=1S/C11H15NO2/c1-8(12-2)11(13)9-5-4-6-10(7-9)14-3/h4-8,12H,1-3H3
  • Key:VAVRRUJYUFACKA-UHFFFAOYSA-N

3-Methoxymethcathinone (3-MeOMC), also known as meta-methoxymethcathinone (m-MeOMC), is a designer drug of the substituted cathinone family described as a stimulant.[3][2][1]

Similarly to other cathinones, it acts as a monoamine releasing agent, including of serotonin, dopamine, and norepinephrine.[1] However, in contrast to cathinones and amphetamines, 3-MeOMC appears to show selectivity for induction of serotonin and dopamine release over release of norepinephrine, and hence may act as a partially selective serotonin–dopamine releasing agent (SDRA).[1] Its EC50Tooltip half-maximal effective concentration values are 129 nM for dopamine release and 306 nM for serotonin release in vitro, whereas it only induced 68% release of norepinephrine at a concentration of 10 μM.[1] For comparison, other related cathinones, including cathinone, methcathinone, 3-methylmethcathinone (3-MMC; metaphedrone), 4-methylmethcathinone (4-MMC; mephedrone), and 4-methoxymethcathinone (4-MeOMC; methedrone), induced 94 to 101% release of norepinephrine at 10 μM.[1]

3-MeOMC first appeared as an illicit drug after 2014.[3]

  1. ^ a b c d e f Blough BE, Decker AM, Landavazo A, Namjoshi OA, Partilla JS, Baumann MH, et al. (March 2019). "The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes". Psychopharmacology (Berl). 236 (3): 915–924. doi:10.1007/s00213-018-5063-9. PMC 6475490. PMID 30341459.
  2. ^ a b Awuchi CG, Aja MP, Mitaki NB, Morya S, Amagwula IO, Echeta CK, et al. (2 February 2023). "New Psychoactive Substances: Major Groups, Laboratory Testing Challenges, Public Health Concerns, and Community-Based Solutions". Journal of Chemistry. 2023. Wiley: 1–36. doi:10.1155/2023/5852315. ISSN 2090-9071.
  3. ^ a b Carroll FI, Lewin AH, Mascarella SW, Seltzman HH, Reddy PA (April 2021). "Designer drugs: a medicinal chemistry perspective (II)". Ann N Y Acad Sci. 1489 (1): 48–77. Bibcode:2021NYASA1489...48C. doi:10.1111/nyas.14349. PMID 32396701.